Baseline characteristics by number of prior LOT in lenalidomide-refractory patients at first index
| Characteristic . | Overall (N = 1455) . | 1 prior LOT (n = 561) . | 2 prior LOT (n = 566) . | 3 prior LOT (n = 328) . |
|---|---|---|---|---|
| Age, median (IQR), y | 69 (61-76) | 69 (61-75) | 70 (61-76) | 68 (60-75) |
| Female, n (%) | 646 (44.4) | 251 (44.7) | 239 (42.2) | 156 (47.6) |
| Race, n (%) | ||||
| White | 916 (63.0) | 347 (61.9) | 355 (62.7) | 214 (65.2) |
| Black | 241 (16.6) | 88 (15.7) | 97 (17.1) | 56 (17.1) |
| Other/unknown | 298 (20.5) | 126 (22.5) | 104 (18.4) | 58 (17.7) |
| Time from diagnosis to T0, median (IQR), y | 1.7 (0.8-3.3) | 0.7 (0.4-1.4) | 2.2 (1.2-3.5) | 3.3 (2.2-4.8) |
| MM subtype, n (%) | ||||
| IgG | 850 (58.4) | 308 (54.9) | 337 (59.5) | 205 (62.5) |
| Light chain | 266 (18.3) | 110 (19.6) | 88 (15.5) | 68 (20.7) |
| Others | 339 (23.3) | 143 (25.5) | 141 (24.9) | 55 (16.8) |
| Cytogenetic risk, n (%) | ||||
| High∗ | 286 (19.7) | 105 (18.7) | 114 (20.1) | 67 (20.4) |
| Standard | 807 (55.5) | 318 (56.7) | 318 (56.2) | 171 (52.1) |
| Unknown | 362 (24.9) | 138 (24.6) | 134 (23.7) | 90 (27.4) |
| ISS stage, n (%) | ||||
| I | 339 (23.3) | 136 (24.2) | 134 (23.7) | 69 (21.0) |
| II | 322 (22.1) | 137 (24.4) | 117 (20.7) | 68 (20.7) |
| III | 294 (20.2) | 125 (22.3) | 105 (18.6) | 64 (19.5) |
| Unknown | 500 (34.4) | 163 (29.1) | 210 (37.1) | 127 (38.7) |
| ECOG PS, n (%) | ||||
| 0 | 566 (38.9) | 241 (43.0) | 219 (38.7) | 106 (32.3) |
| 1 | 889 (61.1) | 320 (57.0) | 347 (61.3) | 222 (67.7) |
| Hemoglobin at T0, n (%) | ||||
| ≥12 g/dL | 537 (36.9) | 214 (38.1) | 195 (34.5) | 128 (39.0) |
| <12 g/dL | 918 (63.1) | 347 (61.9) | 371 (65.5) | 200 (61.0) |
| Prior stem cell transplant, n (%) | 542 (37.3) | 170 (30.3) | 227 (40.1) | 145 (44.2) |
| Prior treatments, n (%) | ||||
| Bortezomib | 1318 (90.6) | 528 (94.1) | 498 (88.0) | 292 (89.0) |
| Carfilzomib | 226 (15.5) | 24 (4.3) | 100 (17.7) | 102 (31.1) |
| Daratumumab | 166 (11.4) | 21 (3.7) | 89 (15.7) | 56 (17.1) |
| Ixazomib | 133 (9.1) | 11 (2.0) | 64 (11.3) | 58 (17.7) |
| Pomalidomide | 82 (5.6) | 2 (0.4) | 33 (5.8) | 47 (14.3) |
| Thalidomide | 14 (1.0) | 0 | 6 (1.1) | 8 (2.4) |
| Elotuzumab | 37 (2.5) | 0 | 18 (3.2) | 19 (5.8) |
| Isatuximab | 0 | 0 | 0 | 0 |
| Time to progression on last line, n (%) | ||||
| ≤4 mo | 338 (23.2) | 132 (23.5) | 133 (23.5) | 73 (22.3) |
| >4 mo | 1117 (76.8) | 429 (76.5) | 433 (76.5) | 255 (77.7) |
| Refractory status, n (%) | ||||
| PI | 1036 (71.2) | 364 (64.9) | 402 (71.0) | 270 (82.3) |
| Anti-CD38 antibody | 97 (6.7) | 15 (2.7) | 48 (8.5) | 34 (10.4) |
| Characteristic . | Overall (N = 1455) . | 1 prior LOT (n = 561) . | 2 prior LOT (n = 566) . | 3 prior LOT (n = 328) . |
|---|---|---|---|---|
| Age, median (IQR), y | 69 (61-76) | 69 (61-75) | 70 (61-76) | 68 (60-75) |
| Female, n (%) | 646 (44.4) | 251 (44.7) | 239 (42.2) | 156 (47.6) |
| Race, n (%) | ||||
| White | 916 (63.0) | 347 (61.9) | 355 (62.7) | 214 (65.2) |
| Black | 241 (16.6) | 88 (15.7) | 97 (17.1) | 56 (17.1) |
| Other/unknown | 298 (20.5) | 126 (22.5) | 104 (18.4) | 58 (17.7) |
| Time from diagnosis to T0, median (IQR), y | 1.7 (0.8-3.3) | 0.7 (0.4-1.4) | 2.2 (1.2-3.5) | 3.3 (2.2-4.8) |
| MM subtype, n (%) | ||||
| IgG | 850 (58.4) | 308 (54.9) | 337 (59.5) | 205 (62.5) |
| Light chain | 266 (18.3) | 110 (19.6) | 88 (15.5) | 68 (20.7) |
| Others | 339 (23.3) | 143 (25.5) | 141 (24.9) | 55 (16.8) |
| Cytogenetic risk, n (%) | ||||
| High∗ | 286 (19.7) | 105 (18.7) | 114 (20.1) | 67 (20.4) |
| Standard | 807 (55.5) | 318 (56.7) | 318 (56.2) | 171 (52.1) |
| Unknown | 362 (24.9) | 138 (24.6) | 134 (23.7) | 90 (27.4) |
| ISS stage, n (%) | ||||
| I | 339 (23.3) | 136 (24.2) | 134 (23.7) | 69 (21.0) |
| II | 322 (22.1) | 137 (24.4) | 117 (20.7) | 68 (20.7) |
| III | 294 (20.2) | 125 (22.3) | 105 (18.6) | 64 (19.5) |
| Unknown | 500 (34.4) | 163 (29.1) | 210 (37.1) | 127 (38.7) |
| ECOG PS, n (%) | ||||
| 0 | 566 (38.9) | 241 (43.0) | 219 (38.7) | 106 (32.3) |
| 1 | 889 (61.1) | 320 (57.0) | 347 (61.3) | 222 (67.7) |
| Hemoglobin at T0, n (%) | ||||
| ≥12 g/dL | 537 (36.9) | 214 (38.1) | 195 (34.5) | 128 (39.0) |
| <12 g/dL | 918 (63.1) | 347 (61.9) | 371 (65.5) | 200 (61.0) |
| Prior stem cell transplant, n (%) | 542 (37.3) | 170 (30.3) | 227 (40.1) | 145 (44.2) |
| Prior treatments, n (%) | ||||
| Bortezomib | 1318 (90.6) | 528 (94.1) | 498 (88.0) | 292 (89.0) |
| Carfilzomib | 226 (15.5) | 24 (4.3) | 100 (17.7) | 102 (31.1) |
| Daratumumab | 166 (11.4) | 21 (3.7) | 89 (15.7) | 56 (17.1) |
| Ixazomib | 133 (9.1) | 11 (2.0) | 64 (11.3) | 58 (17.7) |
| Pomalidomide | 82 (5.6) | 2 (0.4) | 33 (5.8) | 47 (14.3) |
| Thalidomide | 14 (1.0) | 0 | 6 (1.1) | 8 (2.4) |
| Elotuzumab | 37 (2.5) | 0 | 18 (3.2) | 19 (5.8) |
| Isatuximab | 0 | 0 | 0 | 0 |
| Time to progression on last line, n (%) | ||||
| ≤4 mo | 338 (23.2) | 132 (23.5) | 133 (23.5) | 73 (22.3) |
| >4 mo | 1117 (76.8) | 429 (76.5) | 433 (76.5) | 255 (77.7) |
| Refractory status, n (%) | ||||
| PI | 1036 (71.2) | 364 (64.9) | 402 (71.0) | 270 (82.3) |
| Anti-CD38 antibody | 97 (6.7) | 15 (2.7) | 48 (8.5) | 34 (10.4) |
IgG, immunoglobulin G; IQR, interquartile range.
Defined as the presence of ≥1 del17p, t(4;14), or t(14;16) mutation.